Surface Antigen

Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress.

Extending dosing of a novel GalNAc-small interfering RNA brought most patients’ surface antigen levels of hepatitis B virus under control, according to a presenter at the International Liver Congress.

It is feasible for patients with negative HBV e-antigen chronic hepatitis B to discontinue nucleos(t)ide analogues therapy with low quantitative hepatitis B surface antigen levels, per a presentation at The Liver Meeting Digital Experience.